Preparing your medspa for exit in 2026 is a 12-18 month playbook because medspa M&A is in active land-grab mode. PE platforms are paying 5-10x EBITDA for platform-quality operators (multi-location, physician-supervised, recurring membership revenue above 40%). Named consolidators: Advanced Dermatology (Advent), Ideal Image (L Catterton), LaserAway (Ares), plus regional platforms. What buyers focus on: physician-supervision compliance, membership program economics, ancillary attach rate (injectables, laser, body contouring), and staff retention. What kills medspa valuations: single-provider dependence, corporate-practice-of-medicine violations, and coding compliance issues.
Last updated: 2026-06-18
How to Prepare Your Medspa for Sale or Exit (2026)
Medical spas are one of the fastest-consolidating healthcare-adjacent categories in 2026. PE-backed medspa platforms acquired more than 260 single-site and small-chain medspas in the U.S. last year. The category is in active land-grab mode: platforms are paying premium multiples for clean, growing medspas with diversified service lines. If you own a profitable medspa with $500K+ of provider-net EBITDA, you have a real exit window right now.
This page walks through the 18 to 24 month preparation runway that delivers a clean exit at the top end of current pricing.
The Medspa Buyer Landscape in 2026
- PE-backed medspa platforms. Schweiger Dermatology (Pinnacle Dermatology / Vesey Street), Skintology MD, Eden Med, Ageless Mens Health, LaserAway. These are the bulk-acquirers of $500K to $3M EBITDA medspas.
- Dermatology-adjacent platforms. Forefront, U.S. Dermatology Partners, Schweiger — increasingly acquiring medspas as service-line extensions to their derm platforms.
- Independent sponsors and family offices. Active in single-location and small-chain (2 to 5 location) acquisitions.
- Strategic acquirers. Larger medspa chains acquiring single locations to fill geographic gaps.
What Medspa Buyers Pay in 2026
- Single-location medspa, $300K to $750K EBITDA: 4 to 6x EBITDA (SBA-financed, often search fund buyers)
- Single-location medspa, $750K to $2M EBITDA: 5 to 8x EBITDA (PE add-on territory)
- Multi-location chain (3+ locations), $2M+ EBITDA: 7 to 10x EBITDA (platform candidate)
- Branded chain (5+ locations, known brand), $3M+ EBITDA: 9 to 12x EBITDA
The biggest variables are: revenue per location, service-line diversification (injectables vs. lasers vs. body contouring), provider retention, and whether the founder is also the primary injector.
The 18-Month Pre-Sale Runway
Month 18 to 12: Provider and Operations Independence
- Reduce founder-injector concentration. If you (the founder) generate more than 40% of injectable revenue, you’re a major valuation risk. Hire or promote a second injector and build their book to at least 25% of total revenue over 12 months.
- Document provider compensation structures. Hourly vs. commission, retention clauses, non-competes. Buyers will spend significant diligence time here.
- Build supplier diversification. Allergan, Galderma, Merz, Revance — if you’re sole-sourced on a key product, build a backup.
- Lock in your space. Lease renewals matter. A 5+ year remaining lease at favorable rent is a real asset.
Month 12 to 6: Financial and Operational Cleanup
- Accrual accounting. Most medspas run on cash-basis QuickBooks. Switch to accrual at least 12 months before sale. Defer revenue tied to packages/series, recognize as services delivered.
- Track service-line revenue separately. Buyers want to see injectables vs. lasers vs. body contouring vs. memberships broken out monthly for at least 24 months.
- Membership / recurring revenue is gold. If you have monthly subscription members, document it precisely: count, average revenue per member, retention rate, churn. This is the single most valuable revenue stream in medspa M&A.
- Get a sell-side QoE. Particularly important for medspas because of the package-revenue and gift-card-liability accounting nuances buyers will scrutinize.
Month 6 to 0: Sale Process
- Sign with a medspa-specialist advisor. Generic healthcare M&A brokers don’t know the medspa platform landscape. You need someone with active relationships to the named platforms above.
- Prepare your data room. 36 months monthly financials, provider rosters, service-line breakdowns, membership data, lease, equipment list (lasers, IPL, body contouring devices), supplier contracts, insurance, software (Boulevard, Mindbody, Aesthetic Record, AestheticsPro).
- Run a quiet, sequential process. Confidentiality matters in medspa more than most categories — patient retention and provider loyalty are sensitive to public sale rumors.
- Negotiate carefully on packages and gift cards. Unredeemed packages and gift card liabilities are a major working capital adjustment in medspa deals. Get this resolved in the LOI.
What Kills Medspa Valuations
- Founder-injector dependency. If 60%+ of injectable revenue is from the founder, the multiple drops 1 to 2x.
- Heavy package liabilities. Six-figure unredeemed packages = working capital adjustment that comes off the seller’s proceeds.
- Single-supplier concentration. Sole-sourced on Allergan or Galderma without backups is a flagged risk.
- State scope-of-practice issues. States with restrictive medical-director laws (Texas, Florida specific rules) require careful structure documentation.
- Lease that doesn’t transfer. Landlord refusing assignment or wanting to renegotiate at close kills deal economics.
- Pricing inconsistency. If you’re running constant 50% promotions, buyers normalize your revenue downward.
Regulatory Diligence
Medspa M&A diligence always includes:
- Medical director agreement (most states require an MD or DO as medical director)
- Provider licensing and certifications (esthetician, RN, NP scope-of-practice in each state)
- Good faith exam compliance (most states require an MD/NP exam before first injection)
- Corporate Practice of Medicine compliance (varies by state; California and Texas particularly strict)
- HIPAA compliance audit
Resolve any open issues before the LOI. Buyers will discover them in diligence and either renegotiate or walk.
Owner Transition
- PE platforms: Usually want the founder to stay 18 to 36 months, especially if the founder is a primary provider. Equity rollover (10 to 20%) is standard.
- Strategic acquirers: Variable transition — 6 to 18 months depending on whether they have their own clinical leadership.
- Search funders: Less common in medspa because of the clinical leadership requirement; when they do show up, they typically partner with a hired medical director.
How CT Acquisitions Handles Medspa Exits
We run direct introductions to a vetted network of medspa-active platforms, derm consolidators, and family offices. Each introduction is matched to the platform’s specific mandate (geography, service-line focus, single-site vs. multi-site). Our buy-side fee is a flat 2% of EV at close.
Related Reading
Ready to Plan Your Exit?
Every founder’s situation is different. A short conversation gives you a real number for your specific business.